Additionally, the treatment of M2 macrophages with leptin activates the IL-8 promotor through the p38/MAPK and MAPK/ERK1/2 pathways leading to increased IL-8 secretion resulting in enhanced tumor growth in vivo and increased migration and invasiveness in breast cancer cell lines (127). The gene discussed is CXCL8; the disease is breast carcinoma.